Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body (American Heart Association, 2017b). HF commonly occurs in people older than 50 years of age, and severity increases progressively with age (Mosterd and Hoes, 2007). The symptoms can develop quickly, such as in acute HF (AHF), at which time the patient needs to be hospitalized. However, in chronic HF (CHF), the symptoms develop gradually (National Health Service, 2018).
GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and reports to build the forecast for the diagnosed incident cases of HF and the diagnosed prevalent cases of CHF in the 8MM. GlobalData epidemiologists applied the incidence and prevalence of HF drawn from the above sources to each country’s population to calculate the number of estimated diagnosed incident cases of AHF hospitalizations and diagnosed prevalent cases for HF severity according to NYHA functional classification and AHA staging system.
The following data describes the epidemiology of HF. In the 8MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of HF from 2,974,022 cases in 2018 to 3,638,957 cases in 2028, at an Annual Growth Rate (AGR) of 2.24%. When examining the AGR of diagnosed incidence of HF in individual markets, GlobalData epidemiologists forecast that the US will see the highest AGR of 2.91% during the forecast period, while Germany will show the lowest AGR of 1.25%. Among the 8MM, the US had the highest number of diagnosed incident cases of HF in 2018 and 2028, at 1,113,104 cases and 1,437,401 cases, respectively.
Scope
The Heart Failure Epidemiology Report and Model provide an overview of the risk factors and global trends of Heart Failure (HF) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan and China).
This report includes a 10-year epidemiological forecast for the diagnosed incident cases of HF and diagnosed prevalent cases of chronic heart failure (CHF) segmented by age, sex, and ejection fraction. It also includes acute HF (AHF) hospitalizations, prevalent cases of CHF segmented by New York Heart Association (NYHA) functional Classes I–IV and American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Stages. Additionally, the model includes a 10-year epidemiological forecast for various comorbidities of CHF.
The HF epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The HF Epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global HF market.
Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
Understand magnitude of HF population by its severity.
